High glucose attenuates VEGF expression in rat multipotent adult progenitor cells in association with inhibition of JAK2/STAT3 signalling
Zehao Liu
Davis Heart & Lung Research Institute and Division of Cardiovascular Medicine, The Ohio State University Medical Center, Columbus, OH, USA
Xiangya Medical School of Central South University, Changsha, Hunan, China
Search for more papers by this authorMinxiang Lei
Xiangya Medical School of Central South University, Changsha, Hunan, China
Search for more papers by this authorYuehua Jiang
Stem Cell Institute, University of Minnesota Medical School, Minneapolis, MN, USA
Search for more papers by this authorHong Hao
Davis Heart & Lung Research Institute and Division of Cardiovascular Medicine, The Ohio State University Medical Center, Columbus, OH, USA
Search for more papers by this authorLing Chu
Davis Heart & Lung Research Institute and Division of Cardiovascular Medicine, The Ohio State University Medical Center, Columbus, OH, USA
Search for more papers by this authorJian Xu
Davis Heart & Lung Research Institute and Division of Cardiovascular Medicine, The Ohio State University Medical Center, Columbus, OH, USA
Search for more papers by this authorMin Luo
Davis Heart & Lung Research Institute and Division of Cardiovascular Medicine, The Ohio State University Medical Center, Columbus, OH, USA
Search for more papers by this authorCatherine M. Verfaillie
Stem Cell Institute, University of Minnesota Medical School, Minneapolis, MN, USA
Search for more papers by this authorJay L. Zweier
Davis Heart & Lung Research Institute and Division of Cardiovascular Medicine, The Ohio State University Medical Center, Columbus, OH, USA
Search for more papers by this authorCorresponding Author
Zhenguo Liu
Davis Heart & Lung Research Institute and Division of Cardiovascular Medicine, The Ohio State University Medical Center, Columbus, OH, USA
Chongqing Medical University, Chongqing, China
Correspondence to: Zhenguo LIU, M.D., Ph.D.,Davis Heart & Lung Research Institute,The Ohio State University Medical Center,Room 260 DHLRI; 473 West 12th Ave,Columbus, OH 43210, USA.Tel.: +614-247-8435Fax: +614-293-5614E-mail: [email protected]Search for more papers by this authorZehao Liu
Davis Heart & Lung Research Institute and Division of Cardiovascular Medicine, The Ohio State University Medical Center, Columbus, OH, USA
Xiangya Medical School of Central South University, Changsha, Hunan, China
Search for more papers by this authorMinxiang Lei
Xiangya Medical School of Central South University, Changsha, Hunan, China
Search for more papers by this authorYuehua Jiang
Stem Cell Institute, University of Minnesota Medical School, Minneapolis, MN, USA
Search for more papers by this authorHong Hao
Davis Heart & Lung Research Institute and Division of Cardiovascular Medicine, The Ohio State University Medical Center, Columbus, OH, USA
Search for more papers by this authorLing Chu
Davis Heart & Lung Research Institute and Division of Cardiovascular Medicine, The Ohio State University Medical Center, Columbus, OH, USA
Search for more papers by this authorJian Xu
Davis Heart & Lung Research Institute and Division of Cardiovascular Medicine, The Ohio State University Medical Center, Columbus, OH, USA
Search for more papers by this authorMin Luo
Davis Heart & Lung Research Institute and Division of Cardiovascular Medicine, The Ohio State University Medical Center, Columbus, OH, USA
Search for more papers by this authorCatherine M. Verfaillie
Stem Cell Institute, University of Minnesota Medical School, Minneapolis, MN, USA
Search for more papers by this authorJay L. Zweier
Davis Heart & Lung Research Institute and Division of Cardiovascular Medicine, The Ohio State University Medical Center, Columbus, OH, USA
Search for more papers by this authorCorresponding Author
Zhenguo Liu
Davis Heart & Lung Research Institute and Division of Cardiovascular Medicine, The Ohio State University Medical Center, Columbus, OH, USA
Chongqing Medical University, Chongqing, China
Correspondence to: Zhenguo LIU, M.D., Ph.D.,Davis Heart & Lung Research Institute,The Ohio State University Medical Center,Room 260 DHLRI; 473 West 12th Ave,Columbus, OH 43210, USA.Tel.: +614-247-8435Fax: +614-293-5614E-mail: [email protected]Search for more papers by this authorAbstract
This study was to investigate the effect of high glucose (HG) on vascular endothelial growth factor (VEGF) expression in bone marrow stem cells and JAK2/STAT-3 signalling. Adult rat bone marrow multipotent progenitor cells (rMAPCs) were cultured to evaluate VEGF expression (both mRNA and protein) with or without exposure to HG for up to 48 hrs using RT-PCR and ELISA. JAK2 and STAT3 phosphorylation in rMAPCs was analysed by Western blotting. With cells in normal media, VEGF mRNA level after 24 hrs of culture was significantly increased by 15 times over baseline (day 0) with detectable level of VEGF protein intracellularly using immunofluorescence staining. Although there was no measurable VEGF in the media after 24 hrs of culture, a significant amount of VEGF was detected in the media after 48 hrs of incubation. VEGF expression was associated with constitutive activation of JAK2 and STAT3 in rMAPCs. However, VEGF mRNA level was significantly reduced without detectable VEGF in the media when rMAPCs exposed to HG for 48 hrs. Tyrosine-phosphorylation of JAK2 and STAT3 and nuclear translocation of phosphorylated STAT3 were significantly decreased in the cells exposed to HG for 48 hrs. When JAK2 and STAT3 phosphorylation was blocked by the selective inhibitor AG490, VEGF mRNA level was significantly decreased in rMAPCs in normal media by 80% with no detectable VEGF in the media. VEGF expression was significantly suppressed in rMAPCs cultured in HG media that was further reduced by AG490. VEGF expression in rMAPCs is impaired by HG possibly through inhibition of JAK2/STAT3 signalling.
References
- 1 Cooper ME, Bonnet F, Oldfield M, et al . Mechanisms of diabetic vasculopathy: an overview. Am J Hypertens. 2001; 14: 475–86.
- 2 Cull CA, Jensen CC, Retnakaran R, et al . Impact of the metabolic syndrome on macrovascular and microvascular outcomes in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study 78. Circulation. 2007; 116: 2119–26.
- 3 Kanwar YS, Wada J, Sun L, et al . Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med. 2008; 233: 4–11.
- 4 Rahman S, Rahman T, Ismail AA, et al . Diabetes-associated macrovasculopathy: pathophysiology and pathogenesis. Diabetes Obes Metab. 2007; 9: 767–80.
- 5 Asakawa H, Tokunaga K, Kawakami F. Comparison of risk factors of macrovascular complications. Peripheral vascular disease, cerebral vascular disease, and coronary heart disease in Japanese type 2 diabetes mellitus patients. J Diabetes Complications. 2000; 14: 307–13.
- 6 Shah IM, Ghosh SK, Collier A. Stroke presentation in Type 2 diabetes and the metabolic syndrome. Diabetes Res Clin Pract. 2008; 79: e1–4.
- 7 Klein L, Gheorghiade M. Management of the patient with diabetes mellitus and myocardial infarction: clinical trials update. Am J Med. 2004; 116: 47S–63S.
- 8 Tapp RJ, Shaw JE, de Courten MP, et al . Foot complications in Type 2 diabetes: an Australian population-based study. Diabet Med. 2003; 20: 105–13.
- 9 Guerci B, Böhme P, Kearney-Schwartz A, et al . Endothelial dysfunction and type 2 diabetes. Part 2: altered endothelial function and the effects of treatments in type 2 diabetes mellitus. Diabetes Metab. 2001; 27: 436–47.
- 10 Pănuş C, Moţa M, Vladu D, et al . The endothelial dysfunction in diabetes mellitus. Rom J Intern Med. 2003; 41: 27–33.
- 11 Bauer SM, Bauer RJ, Liu ZJ, et al . Vascular endothelial growth factor-C promotes vasculogenesis, angiogenesis, and collagen constriction in three-dimensional collagen gels. J Vasc Surg. 2005; 41: 699–707.
- 12 Sakurai MK, Lee S, Arsenault DA, et al . Vascular endothelial growth factor accelerates compensatory lung growth after unilateral pneumonectomy. Am J Physiol Lung Cell Mol Physiol. 2007; 292: L742–7.
- 13 Wang M, Crisostomo PR, Herring C, et al . Human progenitor cells from bone marrow or adipose tissue produce VEGF, HGF, and IGF-I in response to TNF by a p38 MAPK-dependent mechanism. Am J Physiol Regul Integr Comp Physiol. 2006; 291: R880–4.
- 14 Guarita-Souza LC, Carvalho KA, Woitowicz V, et al . Simultaneous autologous transplantation of cocultured mesenchymal stem cells and skeletal myoblasts improves ventricular function in a murine model of Chagas disease. Circulation. 2006; 114: I120–4.
- 15 Tang YL, Zhao Q, Qin X, et al . Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction. Ann Thorac Surg. 2005; 80: 229–36.
- 16 Tse HF, Siu CW, Zhu SG, et al . Paracrine effects of direct intramyocardial implantation of bone marrow derived cells to enhance neovascularization in chronic ischaemic myocardium. Eur J Heart Fail. 2007; 9: 747–53.
- 17 Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene. 2000; 19: 2548–56.
- 18 Calò V, Migliavacca M, Bazan V, et al . STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol. 2003; 197: 157–68.
- 19 Wang M, Zhang W, Crisostomo P, et al . STAT3 mediates bone marrow mesenchymal stem cell VEGF production. J Mol Cell Cardiol. 2007; 42: 1009–15.
- 20 Becker S, Groner B, Muller CW. Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature. 1998; 394: 145–51.
- 21 Lamb P, Seidel HM, Haslam J, et al . STAT protein complexes activated by interferon-gamma and gp130 signaling molecules differ in their sequence preferences and transcriptional induction properties. Nucleic Acids Res. 1995; 23: 3283–9.
- 22 Wincewicz A, Sulkowska M, Koda M, et al . STAT3, HIF-1alpha, EPO and EPOR – signaling proteins in human primary ductal breast cancers. Folia Histochem Cytobiol. 2007; 45: 81–6.
- 23 Bartoli M, Gu X, Tsai NT, et al . Vascular endothelial growth factor activates STAT proteins in aortic endothelial cells. J Biol Chem. 2000; 275: 33189–92.
- 24 Bartoli M, Platt D, Lemtalsi T, et al. VEGF differentially activates STAT3 in microvascular endothelial cells. FASEB J. 2003; 17: 1562–4.
- 25 Gnecchi M, He H, Noiseux N, et al . Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J. 2006; 20: 661–9.
- 26 Reyes M, Dudek A, Jahagirdar B, et al . Origin of endothelial progenitors in human postnatal bone marrow. J Clin Invest. 2002; 109: 337–46.
- 27 Jiang Y, Jahagirdar BN, Reinhardt RL, et al . Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 2002; 418: 41–9.
- 28 Breyer A, Estharabadi N, Oki M, et al. Multipotent adult progenitor cell isolation and culture procedures. Exp Hematol. 2006; 34: 1596–601.
- 29 Zeng L, Hu Q, Wang X, et al . Bioenergetic and functional consequences of bone marrow-derived multipotent progenitor cell transplantation in hearts with postinfarction left ventricular remodeling. Circulation. 2007; 115: 1866–75.
- 30 Liu Z, Jiang Y, Hao H, et al . Endothelial nitric oxide synthase is dynamically expressed during bone marrow stem cell differentiation into endothelial cells. Am J Physiol Heart Circ Physiol. 2007; 293: H1760–5.
- 31 Abaci A, Oğuzhan A, Kahraman S, et al . Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation. 1999; 99: 2239–42.
- 32 Rivard A, Silver M, Chen D, et al . Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol. 1999; 154: 355–63.
- 33 Bian ZM, Elner SG, Elner VM. Thrombin-induced VEGF expression in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2007; 48: 2738–46.
- 34 Kvanta A. Expression and regulation of vascular endothelial growth factor in choroidal fibroblasts. Curr Eye Res. 1995; 14: 1015–20.
- 35 Chou E, Suzuma I, Way KJ, et al . Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic States: a possible explanation for impaired collateral formation in cardiac tissue. Circulation. 2002; 105: 373–9.
- 36 Hou M, Yang KM, Zhang H, et al . Transplantation of mesenchymal stem cells from human bone marrow improves damaged heart function in rats. Int J Cardiol. 2007; 115: 220–8.
- 37 Davani S, Marandin A, Mersin N, et al . Mesenchymal progenitor cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a rat cellular cardiomyoplasty model. Circulation. 2003; 108: II253–8.
- 38 Aranguren XL, McCue JD, Hendrickx B, et al . Multipotent adult progenitor cells sustain function of ischemic limbs in mice. J Clin Invest. 2008; 118: 505–14.
- 39 Pelacho B, Nakamura Y, Zhang J, et al . Multipotent adult progenitor cell transplantation increases vascularity and improves left ventricular function after myocardial infarction. J Tissue Eng Regen Med. 2007; 1: 51–9.
- 40 Jiang Y, Vaessen B, Lenvik T, et al . Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle, and brain. Exp Hematol. 2002; 30: 896–904.
- 41 Grunewald M, Avraham I, Dor Y, et al . VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell. 2006; 124: 175–89.
- 42 Bian ZM, Elner SG, Elner VM. Regulation of VEGF mRNA expression and protein secretion by TGF-beta2 in human retinal pigment epithelial cells. Exp Eye Res. 2007; 84: 812–22.
- 43 Bussolati B, Dunk C, Grohman M, et al . Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide. Am J Pathol. 2001; 159: 993–1008.
- 44 Niu G, Wright KL, Huang M, et al . Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 2002; 21: 2000–8.
- 45 Funamoto M, Fujio Y, Kunisada K, et al . Signal transducer and activator of transcription 3 is required for glycoprotein 130-mediated induction of vascular endothelial growth factor in cardiac myocytes. J Biol Chem. 2000; 275: 10561–6.
- 46 Jung JE, Lee HG, Cho IH, et al . STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells. FASEB J. 2005; 19: 1296–8.
- 47 Kakizawa H, Itoh M, Itoh Y, et al . The relationship between glycemic control and plasma vascular endothelial growth factor and endothelin-1 concentration in diabetic patients. Metabolism. 2004; 53: 550–5.
- 48 Varma S, Lal BK, Zheng R, et al . Hyperglycemia alters PI3k and Akt signaling and leads to endothelial cell proliferative dysfunction. Am J Physiol Heart Circ Physiol. 2005; 289: H1744–51.
- 49 Sheu ML, Ho FM, Yang RS, et al . High glucose induces human endothelial cell apoptosis through a phosphoinositide 3-kinase-regulated cyclooxygenase-2 pathway. Arterioscler Thromb Vasc Biol. 2005; 25: 539–45.
- 50 Ghilardi N, Ziegler S, Wiestner A, et al . Defective STAT signaling by the leptin receptor in diabetic mice. Proc Natl Acad Sci USA. 1996; 93: 6231–5.
- 51 Jiang BH, Zheng JZ, Aoki M, et al . Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci USA. 2000; 97: 1749–53.